Growth Metrics

Resmed (RMD) Cash from Restructuring (2023)

Resmed (RMD) has disclosed Cash from Restructuring for 1 consecutive years, with $9.2 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Cash from Restructuring changed N/A year-over-year to $9.2 million, compared with a TTM value of $9.2 million through Mar 2025, changed N/A, and an annual FY2024 reading of $33.2 million, up 262.2% over the prior year.
  • Cash from Restructuring was $9.2 million for Q2 2023 at Resmed.
  • Across five years, Cash from Restructuring topped out at $9.2 million in Q2 2023 and bottomed at $9.2 million in Q2 2023.